Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989586 · ClinicalTrials.gov registry record · Phase 1
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Beth Christian.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00989586: Completed Phase 1 study, sponsored by Beth Christian.
NCT00989586 is a Phase 1 study that has completed, run by Beth Christian. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00989586, a Phase 1 study, has completed, sponsored by Beth Christian.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.
Primary Outcome
Dose-limiting toxicity was assessed during induction therapy for phase I.
Interventions
- BIOLOGICAL milatuzumab
- BIOLOGICAL veltuzumab
- PROCEDURE Correlative/Special Studies
- PROCEDURE Quantitative T-, B-, and NK cell subsets
- PROCEDURE Pharmacokinetics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
What the finished NCT00989586 record still lists
NCT00989586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 5 interventions - of which milatuzumab is the first listed.
NCT00989586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00989586 about?
NCT00989586 is a clinical study titled "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma". A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.
What is the current status of trial NCT00989586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2009-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00989586?
The interventions under investigation include: milatuzumab (BIOLOGICAL), veltuzumab (BIOLOGICAL), Correlative/Special Studies (PROCEDURE), Quantitative T-, B-, and NK cell subsets (PROCEDURE), Pharmacokinetics (PROCEDURE).
Who is sponsoring clinical trial NCT00989586?
This trial is sponsored by Beth Christian, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00989586's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia